Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > the potential is huge
View:
Post by knoxt on Jan 28, 2022 9:43am

the potential is huge

Mikee3003 wrote:Indeed CS additional TLT maintenace treatments will be investigated, just takes time to run through the trials.

I'm going to use Rituximab as an example (one of the top selling oncology drugs with annual sale of approximately $8.5 billion, it is also the world's first onclogy monoclonal antibody therapy). My own personal experience with maintenance treatments has been with Rituxamab for my battle with indolent lymphoma (FNHL). FNHL was the first cancer for which the FDA approved Rituximab use. Since it's initial approval in 1997, Rituximab has been through hundreds of various clinical trials, today there are still many trials studying Rituximab.....that's right, still doing trials 25 years after first being approved!

i've used the mAb as an example to hilight how early we are in the TLT story. If we have the success we are expecting with NMIBC we will no doubt be seeing many, many trials for many, many years.

All the Best 
Mikee
 

 

 

Appreciate your example Mikee & wish you the best in your battle.  You bring up a great point...if all goes well, this current trial will likely be the first of very many.  I am hopeful TLT's ACT can be the WD-40 of cancer treatment...used alone, as an adjuvant/add-on, or as a combo treatment for many cancer indications...not to mention infections.  Good luck & wish you well.

Comment by CAinPlap on Jan 28, 2022 10:05am
The importance of the addition of Dr. Vera Madzarevic to oversee the current and future trials cannot be emphasized enough.
Comment by Legit62 on Jan 28, 2022 10:21am
would totally agree with you on this one, but i am still amazed at the thin volume for this stock with such an amazing potential????
Comment by Lesalpes29 on Jan 28, 2022 10:29am
Volume at the moment seems to suggest that People are waiting to see next results. Lot of People already have their shares. I 'm waiting patiently.
Comment by chry200030 on Jan 28, 2022 11:22am
the cure for cancer is huge. Don't get caught chasing when the stock decides to take off. I think we're close..
Comment by Legit62 on Jan 28, 2022 11:27am
I have my shares also, but you would think at this share price a lot more shares would be bought up/ Problem i see is not enough exposure of tltff out there, also the exhange we are on. Hope at some point in time we get to a real exchange.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250